ANDA 77840, held by Hospira. Ondansetron Hydrochloride.
As of Nov 16, 2026, ANDA 77840 (Ondansetron Hydrochloride), held by Hospira, was first approved by FDA on Jan 19, 2007, with 4 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 19, 2007 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Ondansetron HydrochlorideEQ 2MG BASE/ML · injectable;injection | Ondansetron Hydrochloride | Discontinued |
| May 12, 2016 | Supplement 6Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 4Labeling · Standard review | Approved | None posted |
| Dec 8, 2014 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 11, 2013 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jan 19, 2007 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters